Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 218-231 , September 2005

Genetic Changes in Ovarian Cancer

  • Fu-Shing Liu

      Affiliations

    • Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr. Fu-Shing Liu, Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, 160, Section 3, Chung-Kang Road, Taichung, Taiwan

Received 11 July 2005 ,Revised 13 July 2005 ,Accepted 14 July 2005.

References 

  1. Ozols R . Treatment of gynecologic cancer: the US experience . Tumori . 1999;85:S5–11
  2. Pierotti NA , Schichman SA , Sozzi G , Croce CM . Oncogenes . In:  Bast RC ,  Kufe DW ,  Pollock RE ,  Weischselbaum RR ,  Holland JF ,  Frei E editor. Cancer Medicine . Ontario: BC Decker Inc; 2000;p. 56–66
  3. Liu J , Yang G , Thompson-Lanza JA , et al.   A genetically defined model for human ovarian cancer . Cancer Res . 2004;64:1655–1663
  4. Barbacid M . Ras genes . Annu Rev Biochem . 1987;56:779–827
  5. Fabjani G , Kriegshaeuser G , Schuetz A , Prix L , Zeillinger R . Biochip for K-ras mutation screening in ovarian cancer . Clin Chem . 2005;51:784–787
  6. Almoguera C , Shibata D , Forrester K , Martin J , Arnheim N , Perucho M . Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes . Cell . 1988;53:549–554
  7. Bos JL , Fearon ER , Hamilton SR , et al.   Prevalence of ras gene mutations in human colorectal cancers . Nature . 1987;327:293–297
  8. Forrester K , Almoguera C , Han K , Grizzle WE , Perucho M . Detection of high incidence of K-ras oncogenes during human colon tumorigenesis . Nature . 1987;327:298–303
  9. Visvanathan KV , Pocock RD , Summerhayes IC . Preferential and novel activation of H-ras in human bladder carcinomas . Oncogene Res . 1988;3:77–86
  10. Bos JL , Verlaan-de Vries M , van der Eb AJ , et al.   Mutations in N-ras predominate in acute myeloid leukemia . Blood . 1987;69:1237–1241
  11. Bian D , Su S , Mahanivong C , et al.   Lysophosphatidic acid stimulates ovarian cancer cell migration via a ras-MEK kinase 1 pathway . Cancer Res . 2004;64:4209–4217
  12. Bell DA . Origins and molecular pathology of ovarian cancer . Mod Pathol . 2005;18:S19–S32
  13. Hogdall EV , Hogdall CK , Blaakaer J , et al.   K-ras alterations in Danish ovarian tumour patients. From the Danish “Malova” ovarian cancer study . Gynecol Oncol . 2003;89:31–36
  14. Singer G , Oldt R , Cohen Y , et al.   Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma . J Natl Cancer Inst . 2003;95:484–486
  15. Singer G , Kurman RJ , Chang H-W , et al.   Diverse tumorigenic pathways in ovarian serous carcinoma . Am J Pathol . 2002;160:1223–1228
  16. Pohl G , Ho CL , Kurman RJ , Bristow R , Wang TL , Shih IeM . Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations . Cancer Res . 2005;65:1994–2000
  17. Hsu CY , Bristow R , Cha MS , et al.   Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas . Clin Cancer Res . 2004;10:6432–6436
  18. Jamieson S , Alexiadis M , Fuller PJ . Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors . Gynecol Oncol . 2004;95:603–609
  19. Otsuka J , Okuda T , Sekizawa A , et al.   K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma . Med Electron Microsc . 2004;37:188–192
  20. Manavi M , Bauer M , Baghestanian M , et al.   Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium . Tumour Biol . 2001;22:299–309
  21. Amemiya S , Sekizawa A , Otsuka J , Tachikawa T , Saito H , Okai T . Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability . Int J Gynaecol Obstet . 2004;86:371–376
  22. Yang G , Thompson JA , Fang B , Liu J . Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer . Oncogene . 2003;22:5694–5701
  23. Reese DM , Slamon DJ . HER-2/neu signal transduction in human breast and ovarian cancer . Stem Cells . 1997;15:1–8
  24. Shih C , Padhy LC , Murray M , Weinberg RA . Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts . Nature . 1981;290:261–262
  25. Slamon DJ , Godolphin W , Jones LA , et al.   Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer . Science . 1989;244:707–712
  26. Afifi AM , Werness BA , Mark HFL . HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma . Exp Mol Pathol . 1999;66:165–169
  27. Hengstler JG , Lange J , Kett A , Dornhofer N , et al.   Contribution of c-erbB-2 and topoisomerase II alpha to chemoresistance in ovarian cancer . Cancer Res . 1999;59:3206–3214
  28. Meden H , Marx D , Roegglen T , Schauer A , Kuhn W . Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer . Int J Gynecol Pathol . 1998;17:61–65
  29. Tanner B, Kreutz E, Weikel W, Meinert R, Oesch F, Knapstein PG, et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma . Gynecol Oncol . 1996;62:268–277
  30. Meden H , Kuhn W . Overexpression of the oncogene c-erbB- 2 (HER2/neu) in ovarian cancer: a new prognostic factor . Eur J Obstet Gynecol Reprod Biol . 1997;71:173–179
  31. Pegram MD , Finn RS , Arzoo K , Beryt M , Pietras RJ , Slamon DJ . The effect of HER-2/neu overexpression on chemo-therapeutic drug sensitivity in human breast and ovarian cancer cells . Oncogene . 1997;15:537–547
  32. Tsai TC, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, et al. Enhanced chemoresistance by elevation of p185neu level in HER2/neu-transfected human lung cancer cells . J Natl Cancer Inst . 1995;87:682–684
  33. Yu D , Liu B , Tan M , Li J , Wang SS , Hung MC . Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms . Oncogene . 1996;13:1359–1365
  34. Riener EK , Amold N , Kommoss F , Lauinger S , Pfisterer J . The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study . Gynecol Oncol . 2004;95:89–94
  35. Mancini A , Koch A , Wilms R , Tamura T . c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms . J Biol Chem . 2002;277:14635–14640
  36. Roussel MF , Downing JR , Rettenmier CW , Sherr CJ . A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential . Cell . 1988;55:979–988
  37. Woolford J , McAuliffe A , Rohrschneider LR . Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype . Cell . 1988;55:965–977
  38. Suzuki M , Sekiguchi I , Ohwada M , et al.   Expression of c-fms proto-oncogene product by ovarian cancer cell lines with effects of macrophage colony-stimulating factor on proliferation . Oncology . 1996;53:99–103
  39. Yokoyama Y , Morishita S , Takahashi Y , Hashimoto M , Tamaya T . Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme . Br J Cancer . 1997;76:977–982
  40. Wu R , Lin L , Beer DG , et al.   Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas . Am J Pathol . 2003;162:1603–1610
  41. Galmozzi E , Casalini P , Iorio MV , Casati B , Olgiati C , Menard S . HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA . J Cell Physiol . 2004;200:82–88
  42. Casalini P , Botta L , Menard S . Role of p53 in HER2-induced proliferation or apoptosis . J Biol Chem . 2001;276:12449–12453
  43. Tashiro H , Miyazaki K , Okamura H , Iwai A , Fukumoto M . c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression . Int J Cancer . 1992;50:828–833
  44. Iba T , Kigawa J , Kanamori Y , et al.   Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer . Cancer Sci . 2004;95:418–423
  45. Presneau N , Manderson EN , Tonin PN . The quest for a tumor suppressor gene phenotype . Curr Mol Med . 2003;3:605–629
  46. Paige AJ . Redefining tumour suppressor genes: exceptions to the two-hit hypothesis . Cell Mol Life Sci . 2003;60:2147–2163
  47. Feki A , Irminger-Finger I . Mutational spectrum of p53 mutations in primary breast and ovarian tumors . Crit Rev Oncol Hematol . 2004;52:103–116
  48. Greenblatt MS , Bennett WP , Hollstein M , Harris CC . Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis . Cancer Res . 1994;54:4855–4878
  49. Beroud C , Soussi T . p53 gene mutation: software and database . Nucl Acids Res . 1998;26:200–204
  50. Casey G , Lopez ME , Ramos JC , et al.   DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies . Oncogene . 1996;13:1971–1981
  51. Ceccaroni M , Chieco P , Alboni C , et al.   p53 expression, DNA ploidy and mitotic index as prognostic factors in patients with epithelial ovarian carcinoma . Tumori . 2004;90:600–606
  52. Singer G , Stohr R , Cope L , et al.   Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation . Am J Surg Pathol . 2005;29:218–224
  53. Ho ES , Lai CR , Hsieh YT , et al.   p53 mutation is infrequent in clear cell carcinoma of the ovary . Gynecol Oncol . 2001;80:189–193
  54. Kohler MF , Kerns BJ , Humphrey PA , Marks JR , Bast RC , Berchuck A . Mutation and overexpression of p53 in early-stage epithelial ovarian cancer . Obstet Gynecol . 1993;81:643–650
  55. Marks JR , Davidoff AM , Kerns BJ , et al.   Overexpression and mutation of p53 in epithelial ovarian cancer . Cancer Res . 1991;51:2979–2984
  56. Reles A , Wen WH , Schmider A , et al.   Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer . Clin Cancer Res . 2001;7:2984–2997
  57. Johnstone RW , Ruefli AA , Lowe SW . Apoptosis: a link between cancer genetics and chemotherapy . Cell . 2002;108:153–164
  58. Kigawa J , Sato S , Shimada M , et al.   p53 gene status and chemosensitivity in ovarian cancer . Hum Cell . 2001;14:165–171
  59. Buttitta F , Marchetti A , Gadducci A , et al.   p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study . Br J Cancer . 1997;75:230–235
  60. Righetti SC , Della Torre G , Pilotti S , et al.   A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma . Cancer Res . 1996;56:689–693
  61. Bergh J , Norberg T , Sjogren S , Lindgren A , Holmberg L . Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy . Nat Med . 1995;1:1029–1034
  62. Di Leo A , Bajetta E , Biganzoli L , et al.   An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis . Eur J Cancer . 1995;31:2248–2254
  63. Jacquemier J , Penault-Llorca F , Viens P , et al.   Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression . Anticancer Res . 1994;14:2773–2778
  64. Smith-Sorensen B , Kaern J , Holm R , Dorum A , Trope C , Borresen-Dale AL . Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status . Br J Cancer . 1998;78:375–381
  65. Yazlovitskaya EM , DeHaan RD , Persons DL . Prolonged wild-type p53 protein accumulation and cisplatin resistance . Biochem Biophys Res Commun . 2001;283:732–737
  66. Li L , Luan Y , Wang G , et al.   Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma . Int J Mol Med . 2004;14:257–264
  67. Kozubik A , Horvath V , Svihalkova-Sindlerova L , et al.   High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro . Biochem Pharmacol . 2005;69:373–383
  68. Fraser M , Leung BM , Yan X , Dan HC , Cheng JQ , Tsang BK . p53 is a determinant of Xiap/Akt-mediated chemoresistance in human ovarian cancer cells . Cancer Res . 2003;63:7081–7088
  69. Risch HA , McLaughlin JR , Cole DEC , et al.   Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer . Am J Hum Genet . 2001;68:700–710
  70. Cass I , Baldwin RL , Varkey T , Moslehi R , Narod SA , Karlan BY . Improved survival in women with BRCA-associated ovarian carcinoma . Cancer . 2003;97:2187–2195
  71. Robles-Diaz L , Goldfrank DJ , Kauff ND , Robson M , Offit K . Hereditary ovarian cancer in Ashkenazi Jews . Fam Cancer . 2004;3:259–264
  72. Hartman AR , Ford JM . BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair . Nat Genet . 2002;32:180–184
  73. Yang H , Jeffrey PD , Miller J , et al.   BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure . Science . 2002;297:1837–1848
  74. Xu X , Weaver Z , Linke SP , et al.   Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells . Mol Cell . 1999;3:389–395
  75. Thompson ME , Jensen RA , Obermiller PS , Page DL , Holt JT . Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression . Nat Genet . 1995;9:444–450
  76. Hakem R , de la Pompa JL , Sirard C , et al.   The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse . Cell . 1996;85:1009–1023
  77. Boyd J , Sonoda Y , Federici MG , et al.   Clinicopathologic features of BRCA-linked and sporadic ovarian cancer . JAMA . 2000;283:2260–2265
  78. Ben David Y , Chetrit A , Hirsh-Yechezkel G , et al.   Effect of BRCA mutations on the length of survival in epithelial ovarian tumors . J Clin Oncol . 2002;20:463–466
  79. Rubin SC , Benjamin I , Behbakht K , et al.   Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1 . N Engl J Med . 1996;335:1413–1416
  80. Aida H , Takakuwa K , Nagata H , et al.   Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1 . Clin Cancer Res . 1998;4:235–240
  81. Johannsson OT , Ranstam J , Borg A , Olsson H . Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden . J Clin Oncol . 1998;16:397–404
  82. Pharoah PD , Easton DF , Stockton DL , Gayther S , Ponder BA . Survival in familial, BRCA1-associated, and BRCA2- associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group . Cancer Res . 1999;59:868–871
  83. Rhei E , Bogomolniy F , Federici MG , et al.   Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers . Cancer Res . 1998;58:3193–3196
  84. Cvetkovic D , Pisarcik D , Lee C , Hamilton TC , Abdollahi A . Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer . Gynecol Oncol . 2004;95:449–455
  85. Noviello C , Courjal F , Theillet C . Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion . Clin Cancer Res . 1996;2:1601–1606
  86. Li Z , Meng Z , Sayeed A , Shalaby R , Ljung B , Dairkee S . Genome-wide allelotyping of a new in vitro model system reveals early events in breast cancer progression . Cancer Res . 2002;62:5980–5987
  87. Tibiletti M , Bernasconi B , Furlan D , et al.   Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms . Clin Cancer Res . 2001;7:3404–3409
  88. Abdollahi A , Godwin A , Miller P , et al.   Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells . Cancer Res . 1997;57:2029–2034
  89. Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S, Bockaert J, et al. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain . EMBO J . 1997;16:2814–2825
  90. Kas K , Voz ML , Hensen K , Meyen E , Van de Ven W . Transcriptional activation capacity of the novel PLAG family of zinc finger proteins . J Biol Chem . 1998;273:23026–23032
  91. Abdollahi A , Roberts D , Godwin A , et al.   Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors . Oncogene . 1997;14:1973–1979
  92. Abdollahi A , Bao R , Hamilton TC . LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein . Oncogene . 1999;18:6477–6487
  93. Abdollahi A , Pisarcik D , Roberts D , Weinstein J , Cairns P , Hamilton TC . LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24–25, is epigenetically regulated in cancer . J Biol Chem . 2003;278:6041–6049
  94. Shridhar V , Bible KC , Staub J , et al.   Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer . Cancer Res . 2001;61:4258–4265
  95. Strathdee G , Davies BR , Vass JK , Siddiqui N , Brown R . Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene . Carcinogenesis . 2004;25:693–701
  96. Kauffman EC , Robinson VL , Stadler WM , Sokoloff MH , Rinker-Schaeffer CW . Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site . J Urol . 2003;169:1122–1133
  97. Yoshida BA , Sokoloff MM , Welch DR , Rinker-Schaeffer CW . Metastasis-suppressor genes: a review and perspective on an emerging field . J Natl Cancer Inst . 2001;92:1717–1730
  98. Ichikawa T , Ichikawa Y , Isaacs JT . Genetic factors and suppression of metastatic ability of prostatic cancer . Cancer Res . 1991;51:3788–3792
  99. Ichikawa T , Ichikawa Y , Dong J , et al.   Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11 . Cancer Res . 1992;52:3486–3490
  100. Dong JT , Lamb PW , Rinker-Schaeffer CW , et al.   KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 . Science . 1995;268:884–886
  101. White A , Lamb PW , Barrett JC . Frequent downregulation of the KAI1 (CD82) metastasis suppressor protein in human cancer cell lines . Oncogene . 1998;16:3143–3149
  102. Dong JT , Suzuki H , Pin SS , et al.   Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss . Cancer Res . 1996;56:4387–4390
  103. Ueda T , Ichikawa T , Tamaru J , et al.   Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer . Am J Pathol . 1996;149:1435–1440
  104. Houle CD , Ding XY , Foley JF , Afshari CA , Barrett JC , Davis BJ . Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression . Gynecol Oncol . 2002;86:69–78
  105. Liu FS , Dong JT , Chen JT , Hsieh YT , Ho ES , Hung MJ . Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma . Gynecol Oncol . 2000;78:10–15
  106. Viel A , Dall'Agnese L , Canzonieri V , et al.   Suppressive role of the metastasis-related nm23-H1 gene in human ovarian carcinomas: association of high messenger RNA expression with lack of lymph node metastasis . Cancer Res . 1995;55:2645–2650
  107. Hennessy C , Henry JA , May FEB , et al.   Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis . J Natl Cancer Inst . 1991;83:281–285
  108. Royds JA , Cross SS , Silcocks PB , et al.   Nm23 “anti-metastatic” gene product expression in colorectal carcinoma . J Pathol . 1994;172:261–266
  109. Florenes VA , Aamdal S , Myklebost O , et al.   Level of nm23 messenger RNA in metastatic malignant melanoma: inverse correlation to disease progression . Cancer Res . 1992;52:6088–6091
  110. Luo W , Matsuo K , Nagayma Y , et al.   Immunohistochemical analysis of expression of nm23H1/nucleoside diphosphate kinase in human thyroid carcinomas: lack of correlation between its expression and lymph node metastasis . Thyroid . 1994;3:105–109
  111. Higashiyama M , Doi O , Yokouchi H , et al.   Immunohisto-chemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: lack of prognostic value . Br J Cancer . 1992;66:533–536
  112. Scambia G , Ferrandina G , Marone M , et al.   Nm23 in ovarian cancer: correlation with clinical outcome and other clinico-pathological and biochemical prognostic parameters . J Clin Oncol . 1996;14:334–342
  113. Harlozinska A , Bar JK , Gerber J . Nm23 expression in tissue sections and tumor effusion cells of ovarian neoplasms . Int J Cancer . 1996;69:415–419
  114. Schneider J , Romero H , Ruiz R , et al.   Nm23 expression in advanced and borderline ovarian carcinoma . Anticancer Res . 1996;16:1197–1202
  115. Tas F, Tuzlali S, Aydiner A, Saip P, Salihoglu Y, Iplikci A, et al. Prognostic role of nm23 gene expression in patients with ovarian cancer . Am J Clin Oncol . 2002;25:164–167
  116. Cuenda A . Mitogen-activated protein kinase kinase 4 (MKK4) . Int J Biochem Cell Biol . 2000;32:581–587
  117. Yoshida BA , Dubauskas Z , Chekmareva MA , Christiano TR , Stadler WM , Rinker-Schaeffer CW . Mitogen-activated protein kinase kinase 4/stress activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17 . Cancer Res . 1999;59:5483–5487
  118. Kim HL , Vander Griend DJ , Yang X , et al.   Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers . Cancer Res . 2001;61:2833–2837
  119. Yamada SD , Hickson JA , Hrobowski Y , et al.   Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma . Cancer Res . 2002;62:6717–6723

PII: S1028-4559(09)60144-3

doi: 10.1016/S1028-4559(09)60144-3

Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 218-231 , September 2005

Article Tools